Tune in to Global Market Bulletin TV for an extraordinary and in-depth conversation with Dr. Linda Marbán, the Chief Executive Officer of Capricor Therapeutics (NASDAQ: CAPR) and one of the most influential leaders shaping the future of advanced biotechnology. In this exclusive interview, Dr. Marbán offers rare insight into Capricor’s groundbreaking work in cell-based and exosome-based therapeutics—innovations that have the potential to transform the treatment landscape for Duchenne Muscular Dystrophy (DMD) and other serious diseases.
This feature gives viewers a front-row seat into Capricor Therapeutics’ strategic progress and upcoming milestones. Dr. Marbán discusses the company’s anticipated Type-B clinical meeting with the U.S. Food and Drug Administration (FDA), scheduled in early Q3 2023, an essential regulatory dialogue that will shape the next steps for CAP-1002. As its lead therapeutic candidate, CAP-1002 is currently being evaluated in HOPE-3, Capricor’s pivotal Phase 3 clinical trial in DMD—a devastating genetic disorder that affects boys worldwide with no known cure. The therapy has shown encouraging signs of clinical benefit in previous studies and is being closely watched by the global scientific and investment communities.
Dr. Marbán also highlights the enormous promise of Capricor’s StealthX™ Exosome Platform, an advanced delivery technology engineered to support the development of next-generation vaccines, regenerative treatments, and molecular therapeutics such as mRNA and protein-based medicines. Exosomes are emerging at the forefront of biotechnology, and Capricor’s work in this field positions the company as a leading innovator in the global race to develop safe, scalable, and targeted delivery systems for precision medicine.
This interview goes beyond the headlines—offering viewers an insider’s look at the strategic vision, scientific advancements, and mission-driven leadership guiding Capricor’s pipeline. The conversation touches on the company’s progress, partnership ecosystem, scientific discoveries, and long-term commitment to patients living with rare and debilitating diseases. For anyone interested in biotech innovation, gene and cell therapy, or the rapidly expanding field of exosome therapeutics, this is one interview you cannot afford to miss.
About Dr. Linda Marbán, Ph.D.
Chief Executive Officer and Director, Capricor Therapeutics
Dr. Linda Marbán is the CEO and co-founder of Capricor Therapeutics, bringing more than two decades of deep scientific expertise and industry leadership to the advancement of cell and exosome-based therapeutics. She initially joined Capricor in 2005 and became CEO in 2010, later overseeing the company’s transition into Capricor Therapeutics, Inc. in 2013. Under her leadership, Capricor has grown from an early scientific concept into a leading biotechnology company developing late-stage therapeutic programs with global commercial potential.
Before shaping Capricor’s strategic direction, Dr. Marbán held several senior roles at Excigen, Inc., a gene-therapy-focused biotech company where she led business development, operations, and research programs, including groundbreaking work on biological pacemakers. Her foundation in cardiac physiology began in academia, having conducted significant research at The Cleveland Clinic Foundation and Johns Hopkins University, where she later served as Research Assistant Professor in Pediatrics. She holds a Ph.D. in Cardiac Physiology from Case Western Reserve University and a B.S. from the University of Maryland.
Dr. Marbán’s scientific insight, business acumen, and patient-centered leadership continue to guide Capricor as it moves toward potentially life-changing therapeutic breakthroughs.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About Capricor Therapeutics (NASDAQ: CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of cell and exosome-based therapies for rare diseases and complex medical conditions. Its lead candidate, CAP-1002, is an allogeneic cell therapy derived from cardiac cells and is currently in Phase 3 clinical development for Duchenne Muscular Dystrophy (DMD), one of the most severe and life-limiting genetic disorders affecting children globally. CAP-1002 has shown encouraging biomarker and functional outcomes across multiple clinical studies, positioning it as one of the most advanced cell therapy programs in the DMD treatment landscape.
Capricor also maintains a strategic commercial partnership with Nippon Shinyaku Co., Ltd., granting exclusive rights to distribute CAP-1002 in the United States and Japan pending regulatory approval. This partnership ensures a clear and commercially viable path forward should CAP-1002 receive FDA authorization.
Beyond its lead program, Capricor is developing the StealthX™ Exosome Platform, a versatile next-generation delivery technology designed to transport proteins, nucleic acids, and mRNA payloads with high precision. This platform has broad potential applications across infectious disease, regenerative medicine, immunology, oncology, and next-generation vaccine development.
Capricor’s mission is anchored in scientific innovation, patient impact, and industry leadership—driving forward therapeutic technologies that could fundamentally reshape modern medicine.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
